Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma
Benzinga
JANUARY 8, 2024
Johnson & Johnson (NYSE: JNJ ) has announced a merger with Ambrx Biopharma (NASDAQ: AMAM ) that is expected to be completed 2024-H1. Under the terms of the agreement, Johnson & Johnson has agreed to give Ambrx Biopharma $2.00 Ambrx Biopharma Inc is a clinical-stage biologics company.
Let's personalize your content